deltatrials
Recruiting PHASE3 NCT04766177

Role of Bumetanide in Treatment of Autism

Role of Bumetanide in Treatment of Autism Spectrum Disorder in Children

Sponsor: Sherief Abd-Elsalam

Conditions Autism
Interventions Bumetanide Placebo
Updated 3 times since 2021 Last updated: Feb 19, 2021 Started: Jan 1, 2021 Primary completion: Dec 1, 2030 Completion: Dec 1, 2030

Listed as NCT04766177, this PHASE3 trial focuses on Autism and remains actively recruiting participants. Sponsored by Sherief Abd-Elsalam, it has been updated 3 times since 2021, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Change History

3 versions recorded

  1. Sep 2024 — Present [monthly]

    Recruiting PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE3

  3. Mar 2021 — Jul 2024 [monthly]

    Recruiting PHASE3

    First recorded

Jan 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sherief Abd-Elsalam
Data source: Tanta University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Tanta, Egypt